CD274 and neoplasm: Furthermore, triplet regimens (e.g., HDACi + anti–PD-1 + chemotherapy, or STT3 inhibitor + anti–PD-L1 + MEK inhibitor) are under investigation to address tumor heterogeneity and redundant escape pathways.